Introduction
============

Formation of an intimal aortic tear, resulting from uncontrolled hypertension, pregnancy, trauma, bicuspid aortic valve, Marfan syndrome, Ehlers-Danlos syndrome, Turner syndrome, syphilis, cocaine use, or surgical procedures (including aortic or mitral valve repair, coronary artery bypass grafting, cardiac catheterization) allows blood to split the aortic wall into a false and a true lumen.[@b1-ppa-7-319] Patients may be pain-free if the false lumen is connected with the true lumen at the distal portion of the descending aorta.[@b2-ppa-7-319] However, several features put patients at high risk,[@b3-ppa-7-319],[@b4-ppa-7-319] ie, progressive enlargement of the false lumen, remote organ or peripheral artery malperfusion, occlusion of the subclavian or carotid arteries, and compromise of the ostial coronary artery by the false lumen.

Classification of aortic dissection is mainly based on the initial site of the tears,[@b5-ppa-7-319] with type A defined as tears at the ascending artery and type B as tears at the descending artery. In some cases, type B dissection can tear up to the aortic arch and lead to a more complex pattern of dissection.[@b6-ppa-7-319] Although surgical replacement of the aorta is the standard of care for type A dissection,[@b7-ppa-7-319] it is associated with increased mortality in type B dissection. With the development of novel endovascular devices, implantation of a stent graft has been found to produce results comparable with those of surgical procedures.[@b8-ppa-7-319],[@b9-ppa-7-319] Previous study with a small patient size reported an increased event rate if endovascular repair was performed at the acute stage.[@b10-ppa-7-319] As a result, the current study aimed to compare the long-term clinical outcome for patients at the acute versus chronic stage of aortic dissection treated by endovascular repair before and after propensity score matching.

Materials and methods
=====================

Patient population
------------------

Between May 2000 and June 2011, 321 patients with aortic dissection were studied prospectively. Of these patients, 10 died soon after admission, 27 (20 type A, seven type B) underwent surgery, and 110 with type B dissection (48 acute, 62 chronic) were put on maximal medication because they were clinically stable. Finally, 174 patients with type B dissection were transferred to Nanjing First Hospital and treated by implantation of a stent graft, and formed the basis of the present study ([Figure 1](#f1-ppa-7-319){ref-type="fig"}). Our institutional review board approved this study, and full informed consent was obtained from each patient.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria were type B aortic dissection (descending thoracic aorta ≥ 40 mm in diameter at onset of aortic dissection) with complications requiring surgical intervention, including visceral or leg ischemia, aortic rupture, refractory hypertension, refractory pain, or growth of ulcer-like projections.

Exclusion criteria were as follows: distance between the entry tear and left subclavian artery \< 5 mm; abdominal approach not feasible when diameter of the access artery (ie, the femoral and iliac artery) \<7 mm; and existence of complications requiring emergency surgery, including cardiac tamponade, ischemia of the coronary artery or cervical branches, or aortic regurgitation.

Interventional procedure
------------------------

Computed tomography (CT) and calibrated coronary and aortoangiography were performed preoperatively in all patients. In patients with chronic dissection, the diameters of the stent grafts were determined to be approximately 10% larger than that of the aorta proximal to the entry tear, as measured on contrast-enhanced CT. In patients with acute dissection, approximately the same diameter as that of the aorta proximal to the entry tear was adopted as the diameter of the stent graft. The distance between the entry tear and the left subclavian artery was measured on a calibrated angiographic scan in all cases. Three-dimensional reconstruction or multiplanar reconstruction images elaborated from axial CT images were used in some cases to measure the length and shape of the entry tear. The length of the stent graft was 7.0 cm in most cases, in which the entry tear was like a pinhole. However, in some cases, the length of the stent graft was 10--12 cm or longer because the entry tear had a considerable longitudinal length. Percutaneous coronary intervention using a drug-eluting stent was performed just before the stent graft procedure if any epicardial coronary artery had a diameter stenosis ≥ 90% on visual estimation.

Individually selected stent grafts (Talent™, Medtronic Inc, Santa Rosa, CA; Willis™, Microport, Shanghai, People's Republic of China) were used to scaffold up to 20 cm of dissected thoracic aorta. The procedure was performed using digital angiography. The femoral artery could usually accommodate the 24 French stent-graft system, which was advanced over a stiff 260 cm wire navigated in the true lumen and deployed under rapid pacing[@b11-ppa-7-319],[@b12-ppa-7-319] or intravenous injection of a vasodilator drug.[@b13-ppa-7-319] Intentional coverage of the left subclavian artery was accepted to avoid endoleak.[@b14-ppa-7-319] Surgical revascularization of the left subclavian artery was performed at the discretion of the operator based on whether or not the patient developed symptoms related to coverage, ie, ischemia of the arm, brain, or spinal cord. In the presence of arteria lusoria, an incomplete circle of Willis, or a dominant left vertebral artery, a left subclavian artery bypass was placed before stenting.[@b11-ppa-7-319],[@b14-ppa-7-319],[@b15-ppa-7-319] For patients having multiple tears, complete repair of the dissection was encouraged, with additional stents in branch vessels or use of a large bare metal stent in the aorta. Spinal drainage was performed if patients developed symptoms.

Follow-up
---------

Clinical follow-up was performed by visit or telephone contact at one, 3, and 12 months within the first year after the index procedure, and yearly thereafter. Adverse events were monitored throughout the entire study period. Follow-up three-dimensional CT scanning was scheduled at one, 3 and 6 months after the index procedure unless clinical reasons indicated earlier. Surveillance aortoangiography was scheduled at 6 months after the stenting procedure. Clinical outcome and events were classified in accordance with reporting standards of the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery/International Society for Cardiovascular Surgery.[@b11-ppa-7-319],[@b16-ppa-7-319] An outcomes adjudication committee consisting of a cardiac surgeon, a vascular surgeon, and two cardiac interventionalists assessed each complication independently in a blinded fashion, with potential disagreements to be resolved by consensus. With serial tomographic imaging, all patients underwent evaluation for false lumen thrombosis and true lumen dimensions at the level of the dissected aorta.

Definitions
-----------

Dissection was considered an acute event if it occurred \< 2 weeks from onset of symptoms, and was considered chronic when occurring beyond 2 weeks. Complications were classified as access complications (requiring surgical revision, renal failure), procedure-related complications (retrograde dissection, organ or peripheral artery malperfusion, dissection rupture, type I endoleak, and stroke because of subclavian artery occlusion), and nonprocedure-related complications (including myocardial infarction, cancer, and multiple organ failure, or stroke with no relationship to stent grafting). Procedural success was defined as technically successful deployment of the endoprosthesis at the intended target location. Any death that occurred suddenly or could not be related to other causes was classified as being caused by aortic rupture. Reintervention was defined as the need for any surgical conversion or additional endovascular stent graft procedures.

Statistical analysis
--------------------

For continuous variables, binary distribution was tested and differences were evaluated using the independent two-samples *t*-test (if binary distribution) or the Mann--Whitney *U* test (if nonbinary distribution). Categorical variables were compared using the Fisher's Exact test or χ^2^ test. Kaplan--Meier curves for event-free survival rate were generated and compared using the log-rank test. All tests were two-tailed. *P* \< 0.05 was considered to be statistically significant. The data were processed using the Statistical Package for the Social Sciences software package version 17.0 (SPSS, Inc, Chicago, IL, USA).

Propensity score matching was performed to avoid treatment selection bias and potential confounding factors, and to adjust for any significant differences in patient or lesion characteristics. The following variables were selected to calculate the propensity score by binary logistic regression: age, gender, height, weight, hypertension, diabetes, hyperlipidemia, serum creatinine, history of renal dysfunction, alcohol abuse, current smoking, chronic obstructive pulmonary disease, previous stroke, complications at admission (including congestive heart failure, pericardial effusion, acute myocardial infarction, pleural effusion, nonpulsation in peripheral arterial disease), coronary artery diameter stenosis ≥90%, distance of tears to the left subclavian artery, stent number, stent diameter, stent length, left subclavian artery involved, additional tears and their location, and peripheral artery or remote organ malperfusion.

The discrimination and calibration ability of each propensity score model was assessed using the Hosmer-Lemeshow statistic and the area under the receiver operator characteristic curve (procedure-related complication as the state variable, propensity score as the tested variable). The goodness-of-fit statistic was 4.866 (*P* = 0.772) and the area under the receiver operator characteristic curve for the model was 0.677 (ie, the c statistic). The new propensity score was then incorporated to assess the efficacy of stent grafting for the chronic versus acute groups. Hierarchical cluster analysis was used for development of a propensity score, matching pairs with a 1:1 match (nearest neighbor). Patients who did not have pairs were excluded from the final matched population.

Results
=======

Of the 174 patients, 118 were assigned as acute (\<2 weeks) and 56 were assigned as chronic (≥2 weeks), according to time from symptom onset ([Table 1](#t1-ppa-7-319){ref-type="table"}). All patients in the chronic group had tightly controlled hypertension and were pain-free. Baseline characteristics were comparable between the acute and chronic groups, except for the proportion of males (94.1% versus 78.6%, respectively, *P* = 0.004) and alcohol abuse (33.9% versus 17.9%, *P* = 0.032).

Most patients had a single dissection, but patients in the acute group had more multiple tears (24.6% versus 7.1%, [Table 2](#t2-ppa-7-319){ref-type="table"}). Most second tears were localized at the renal artery area, and complete repair was achieved in only one patient. Medication did not limit progression of the false lumen in the chronic group (48.67 ± 5.69 mm versus 36.83 ± 4.77, *P* = 0.001). There were significant differences in stent number and length between the two groups. Coronary angiography was performed at the same stage in nearly 70% of patients and single-vessel disease was seen in 13% of patients, with the left anterior descending artery more often involved in the acute group (16.9% versus 5.4%, *P* = 0.046). Approximately 20% of patients had occluded peripheral arteries, with no significant difference between the groups.

Interventional procedures were successful in all patients ([Table 3](#t3-ppa-7-319){ref-type="table"}). There was one death due to aortic rupture immediately after the stiff wire was positioned in the ascending artery in the acute group. Overall inhospital events and mortality in the acute group were 23.7% and 7.6%, respectively, and were not significantly different from those in the chronic group. Patients in the acute group had a significantly higher rate of procedure-related events (18.6%), than patients in the chronic group (5.4%, *P* = 0.021), but the incidence of individual point of procedure-related events was comparable between the two groups. There were no significant differences in nonprocedure-related events needing surgical repair for access sites, renal dysfunction with or without continuous renal replacement therapy, overall stroke, and bleeding either needing or not needing transfusion between the two groups. Significantly, no patient had paraplegia in either group. Nearly one third of patients had transient fever in hospital. Moreover, at the end of follow-up (mean 3.13 years in the chronic group and 2.76 years in the acute group, *P* = 0.478), overall and aorta-related mortality rates were 11.0% and 7.6%, respectively, in the acute group, and not significantly different from those in the chronic group (3.6% and 3.6%, *P* = 0.148 and *P* = 0.506, respectively, [Figures 2](#f2-ppa-7-319){ref-type="fig"} and [3](#f3-ppa-7-319){ref-type="fig"}). Both the false and true lumen showed significant remodeling over time, with \>93% complete false-lumen thrombosis and evidence of aortic remodeling within 6 months of the index procedure.

By propensity score matching, 51 pairs of patients were matched. There were no statistically significant differences in procedure-related events, nonprocedure-related events, or any other study endpoints between the two groups ([Table 4](#t4-ppa-7-319){ref-type="table"}). By regression analysis, type I endoleak (hazards ratio 0.076, 95% confidence interval 0.022--0.263, *P* \< 0.001) and untreated tear (odds ratio 0.103, 95% confidence interval 0.020--0.176, *P* \< 0.001) were independent risk factors for procedure-related events and death during follow-up before and after matching.

Discussion
==========

The major findings of the current study are as follows. Patients in the acute group had a significantly increased rate of procedure-related events when compared with those in the chronic group, although this difference became smaller after propensity score matching; the chronic false lumen was progressively enlarged despite maximal medical therapy; and the presence of type I endoleak and untreated tears predicted death.

Aorta remodeling over time
--------------------------

Persistent enlargement of the false lumen was seen in 50% of patients in this study. Implantation of a stent graft was associated with significant shrinkage of the false lumen. Although remodeling over the whole aortic artery was not heterogeneous,[@b8-ppa-7-319] our results show that shrinkage of the false lumen was positively correlated with the increase in the true lumen, with no significant difference between the chronic and acute groups. However, reduction in the diameter of the false lumen in the chronic group was greater when compared with that in the acute group. This is not surprising, because patients in the chronic group had a larger false lumen at baseline. Importantly, similar to previous studies,[@b8-ppa-7-319],[@b17-ppa-7-319],[@b18-ppa-7-319] our results confirmed \> 93% complete false-lumen thrombosis. As a result, stent graft provides a strong enough scaffolding for the dissected aorta and puts patients in a stable status via significant aorta remodeling and complete thrombosis of the false lumen.

Clinical outcomes in acute versus chronic patients
--------------------------------------------------

Most studies analyzing clinical events overall in patients with type B dissection[@b19-ppa-7-319]--[@b21-ppa-7-319] have reported lower event rates after endovascular repair than after surgical reconstruction in chronic patients. In their study of a small patient sample (n = 38), Kato et al[@b10-ppa-7-319] reported early and late complication rates of 33% and 36% in acute (\<one month) patients compared with 4% and 0% in chronic (≥one month) patients. However, Kato et al did not report the actual number of patients having a time interval \< 2 weeks from symptom onset. In terms of acute patients (\<2 weeks), Dake et al were the first to report on endovascular stent grafting for treatment of acute aortic dissection in the clinical setting.[@b22-ppa-7-319] They treated 19 patients with acute dissection, and the mortality rate in their series was 21%.

Based on our data, the procedure-related event rate in acute patients was significantly higher than that in the chronic group (*P* = 0.021), and was mainly driven by organ or peripheral artery malperfusion (11.0% versus 3.6%) and type I endoleak (11.9% versus 1.8%), similar to our previous study.[@b23-ppa-7-319] The process of aneurysmal degeneration at the portion proximal to the stent in the acute stage has not been clearly elucidated so far. The present data indicate that persistent enlargement of the false lumen occurred in 50% of patients who survived the acute phase. Therefore, selection of the landing zone and complete coverage of tears were two critical issues in order to avoid endoleak,[@b10-ppa-7-319],[@b23-ppa-7-319] so the stent should be landed at least 3--5 mm proximal to the tear. Furthermore, distortion of the stent system was somewhat inevitable if the descending aorta was extremely tortuous. As a result, a more flexible and dedicated stent system is needed.

Designing a randomized study comparing stent grafting for acute versus chronic type B dissection is impossible in the clinical setting. Because of the presence of differences in baseline characteristics between acute and chronic patients, direct comparison of clinical outcomes of endovascular repair for acute versus chronic dissection is not feasible. Thus, propensity score matching is a useful tool for use in a nonrandomized study in order to minimize selection bias.[@b24-ppa-7-319],[@b25-ppa-7-319] After propensity score matching, the difference in the procedure-related complication rate between the two groups became smaller, even though type I endoleak still tended to be high in the acute group. However, regression analysis before and after propensity score matching consistently showed that type I endoleak and untreated tears were predictors of procedure-related complications and mortality. Again, this underscores the importance of avoiding endoleak.

Untreated tears
---------------

Multiple tears have been reported in some patients from previous studies,[@b1-ppa-7-319]--[@b23-ppa-7-319] but actual rates are not known. From the current study, one quarter of the patients in the acute group had second tears, and complete repair was achieved in only one patient. Because all second tears localized at a level close to the orifice of the renal artery, a site where there are several major arteries taking off, endovascular repair for these additional tears was difficult and dangerous. This is one of the possible explanations for why patients in the acute group had a high incidence of organ or peripheral artery malperfusion. Taking these into consideration, extension of the landing zone to minimize type I endoleak and complete endovascular repairs for all tears is important.

Limitations
-----------

Obviously, classification of patients as chronic or acute was not random, leading to the relative small patient sample in the chronic group. Another limitation was that all patients having type B dissection were not studied systematically, with more stable chronic patients being put on long-term medication. We did not analyze the difference in clinical outcomes between surgical and percutaneous treatment because of the small number of patients in the surgical group. Selection of stent diameter was based on different criteria for chronic and acute patients. This bias could not be excluded when relatively more type I endoleak in acute group was considered, although the stent diameter in the acute group was comparable with that in the chronic group. Finally, the small sample size could be another reason why there was no significant difference in outcome after propensity score matching between the two groups. In conclusion, we found that endovascular repair for acute or chronic type B dissection was safe and feasible, resulting in comparable long-term clinical results between the two groups after propensity score matching.
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###### 

Baseline clinical characteristics

                                               Chronic (n = 56)   Acute (n = 118)   *P*
  -------------------------------------------- ------------------ ----------------- -------
  Age, years                                   53.96 ± 10.69      57.39 ± 11.15     0.052
  Male, n (%)                                  44 (78.6)          111 (94.1)        0.004
  Hypertension, n (%)                          49 (87.5)          102 (86.4)        1.000
   On medication                               8 (14.3)           15 (12.7)         0.151
   With positive family history                3 (5.4)            9 (7.6)           0.671
  Coronary artery disease, n (%)               18 (32.1)          30 (25.4)         0.369
  Diabetes, n (%)                              6 (10.7)           4 (3.4)           0.078
  Hyperlipidemia, n (%)                        2 (3.6)            13 (11.0)         0.148
  Abuse of alcohol, n (%)                      10 (17.9)          40 (33.9)         0.032
  Current smoking, n (%)                       38 (67.9)          71 (60.0)         0.402
  COPD, n (%)                                  2 (3.6)            3 (2.5)           0.657
  Previous stroke, n (%)                       4 (7.1)            5 (4.2)           0.713
  Previous renal dysfunction, n (%)            3 (5.4)            5 (4.2)           0.471
  Complications at admission, n (%)            9 (16.1)           25 (21.2)         0.540
   Congestive heart failure                    1 (1.8)            2 (1.7)           1.000
   Pericardial effusion                        2 (3.6)            2 (1.7)           0.595
   Acute myocardial infarction                 0                  0                 NS
   Pleural effusion                            5 (5.4)            3 (2.5)           0.388
   Non-pulsation at limbs                      0                  9 (7.6)           0.059
  Time from onset of symptom to admission, h   1608 ± 957         34 ± 14           0.001

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Lesions and procedural characteristics

                                               Chronic (n = 56)   Acute (n = 118)   *P*
  -------------------------------------------- ------------------ ----------------- ---------
  No dissections                                                                    0.007
   Single                                      52 (92.9)          89 (75.4)         
   Additional                                  4 (7.1)            29 (24.6)         
   Localized at the renal artery area          4 (100)            29 (100.0)        
   Simultaneously repair                       0                  1 (3.6)           
  Distance of dissection to LSCA, cm           2.49 ± 2.09        2.23 ± 1.36       0.387
  Diameter of false lumen, mm                  38.67 ± 5.69       26.83 ± 4.77      0.001
  Time from onset of symptom to procedure, d   23.29 ± 6.21       4.83 ± 3.65       \<0.001
  Stent number, n                              1.13 ± 0.20        1.76 ± 0.87       0.103
  Stent diameter, mm                           36.45 ± 4.34       36.64 ± 2.68      0.725
  Stent length, mm                             130.84 ± 40.59     136.11 ± 40.83    0.427
  Coronary angiography, n (%)                  38 (67.86)         84 (71.19)        0.257
   1-vessel disease                            6 (10.8)           20 (16.9)         0.203
    LAD lesion                                 3 (5.4)            20 (16.9)         0.046
   Multivessel disease                         0                  8 (6.8)           0.088
  PCI at same stage, n (%)                     3 (5.4)            8 (6.8)           1.000
  Renal artery occlusion, n (%)                4 (7.1)            11 (9.3)          0.777
  Iliac/femoral artery occlusion, n (%)        0                  9 (7.6)           0.059
  LSCA occlusion, n (%)                        3 (5.4)            8 (6.8)           1.000

**Abbreviations:** LSCA, left subclavian artery; LAD, left anterior descending artery; PCI, percutaneous coronary intervention.

###### 

Comparison of clinical results for the acute versus chronic type B aortic dissection groups

                                                   Chronic (n = 56)   Acute (n = 118)   *P* value
  ------------------------------------------------ ------------------ ----------------- -----------
  Follow-up duration, years                        3.13 ± 2.39        2.76 ± 2.39       0.478
  Procedural success, n (%)                        56 (100.00)        118 (100.00)      1.000
  Intraprocedure, n (%)                                                                 
   Aortic rupture                                  0                  1 (0.8)           1.000
   Needing surgical operation                      0                  0                 NS
  Inhospital overall events, n (%)                 6 (10.7)           28 (23.7)         0.064
   Overall death                                   0                  9 (7.6)           0.059
  Procedure-related events, n (%)                  3 (5.4)            22 (18.6)         0.021
   Reverse dissection                              1 (1.8)            1 (0.8)           0.541
   Organ or peripheral artery malperfusion         2 (3.6)            13 (11.0)         0.148
   Dissection rupture                              0                  1 (0.8)           1.000
   Type I leakage                                  1 (1.8)            14 (11.9)         0.039
   LSCA occlusion leading to stroke                0                  2 (1.7)           1.000
  Nonprocedure-related events, n (%)               3 (5.4)            12 (10.2)         0.392
   Acute myocardial infarction                     0                  1 (0.8)           1.000
   Cancer                                          0                  0                 NS
   Multiorgan failure                              0                  3 (2.5)           0.552
   Non-LSCA occlusion leading to stroke            3 (5.4)            7 (5.9)           1.000
  Surgical operation for access site, n (%)        1 (1.8)            3 (2.5)           1.000
  Renal failure, n (%)                             4 (7.1)            18 (15.3)         0.151
   Without needing dialysis                        3 (5.4)            11 (9.3)          0.553
   Needing CRRT                                    1 (1.8)            7 (5.9)           0.439
  Reversible central complications, n (%)          1 (1.8)            10 (8.5)          0.107
  Overall stroke, n (%)                            3 (5.4)            9 (7.6)           0.754
  Paraplegia, n (%)                                0                  0                 NS
  Deep vein thrombosis, n (%)                      1 (1.8)            0                 0.322
  Bleeding, n (%)                                  2 (3.6)            14 (11.9)         0.095
   Needing transfusion                             1 (1.8)            10 (8.5)          0.107
  Fever, n (%)                                     17 (30.4)          32 (27.1)         0.719
  Death by end of follow-up, n (%)                 2 (3.6)            13 (11.0)         0.148
   Aortic-related death                            2 (3.6)            9 (7.6)           0.506
  Change in diameter of true lumen, mm                                                  
   Prior                                           16.35 ± 10.26      18.32 ± 15.79     0.726
   Post                                            24.70 ± 4.55       25.02 ± 4.78      0.805
   1 month                                         26.88 ± 5.21       27.20 ± 5.42      0.819
   3 months                                        27.34 ± 4.09       27.48 ± 6.05      0.867
   6 months                                        28.66 ± 5.67       28.97 ± 5.73      0.902
  Diameter of false lumen at stented segment, mm                                        
   Post                                            20.11 ± 7.35       17.65 ± 7.08      0.702
   1 month                                         18.68 ± 5.43       13.48 ± 4.35      0.430
   3 months                                        17.35 ± 14.65      12.07 ± 10.77     0.047
   6 months                                        15.02 ± 15.63      12.37 ± 13.24     0.582
   Complete thrombosis, n (%)                      53 (94.6)          108 (91.5)        0.707

**Abbreviations:** LSCA, left subclavian artery; CRRT, continuous renal replacement therapy.

###### 

Comparison of worse events between chronic vs acute groups after propensity score matching

                                              Chronic (n = 51)   Acute (n = 51)   *P*
  ------------------------------------------- ------------------ ---------------- -------
  In-hospital overall events, n (%)           6 (11.5)           10 (19.6)        0.289
   Overall death                              0                  3 (5.9)          0.118
  Procedure-related events, n (%)             3 (5.9)            5 (9.8)          0.488
   Reverse dissection                         1 (2.0)            0                1.000
   Malperfusion                               2 (3.9)            2 (3.9)          1.000
   Dissection rupture                         0                  1 (2.0)          0.495
   Type I leakage                             1 (2.0)            5 (9.8)          0.112
   LSCA occlusion leading stroke              0                  1 (2.0)          0.495
  Non-procedure-related events, n (%)         3 (5.9)            6 (11.8)         0.319
   Acutemyocardial infarction                 0                  0                NS
   Cancer                                     0                  0                NS
   Multi-organ failure                        0                  1 (2.0)          0.495
   Non-LSCA occlusion leading stroke          3 (5.9)            4 (7.8)          0.715
  Surgical operation for access site, n (%)   1 (2.0)            0                1.000
  Transient renal failure, n (%)              4 (7.8)            7 (13.7)         0.358
   Without needing dialysis                   3 (5.9)            6 (11.8)         0.319
   Needing CRRT                               1 (2.0)            1 (1.8)          1.000
  Reversable central complications, n (%)     1 (2.0)            10 (8.5)         0.107
  Overall stroke, n (%)                       3 (5.9)            5 (9.8)          0.488
  Paraplegia, n (%)                           0                  0                NS
  Deep venous thrombus, n (%)                 1 (2.0)            0                0.322
  Bleeding, n (%)                             2 (3.9)            2 (3.9)          1.000
   Needing transfusion                        1 (2.0)            1 (1.9)          1.000
  Death at the end of follow-up, n (%)        2 (3.9)            3 (5.9)          0.678
   Aortic-related death                       2 (3.9)            1 (2.0)          1.000

**Abbreviations:** LSCA, left subclavian artery; CRRT, continuous renal replacement therapy.
